This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://linked.opendata.cz/resource/drugbank/drug/DB05038/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB05038/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05038/identifier/drugbank/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB05038/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05038
rdf:type
n3:Drug
n3:description
Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).
n3:generalReferences
# Kaplanski J, Pruneau D, Asa I, Artru AA, Azez A, Ivashkova Y, Rudich Z, Shapira Y: LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J Neurotrauma. 2002 Aug;19(8):953-64. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12225655 # Pruneau D, Paquet JL, Luccarini JM, Defrene E, Fouchet C, Franck RM, Loillier B, Robert C, Belichard P, Duclos H, Cremers B, Dodey P: Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist. Immunopharmacology. 1999 Sep;43(2-3):187-94. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10596852
n3:group
investigational
n3:indication
Investigated for use/treatment in traumatic brain injuries.
owl:sameAs
n12:DB05038
dcterms:title
Anatibant
adms:identifier
n6:3025957 n7:23927468 n8:2291585 n9:DB05038
n3:mechanismOfAction
Anatibant is a new potent and selective non-peptide antagonist of the bradyknin B2 receptor. Anatibant crosses the blood brain barrier, reduces brain edema formation and brain damage, and improves neurological function following experimental traumatic brain injury. The underlying mechanisms are still not well understood. So far bradykinin B2 receptor-mediated neuroprotection was mainly explained by the reduction of vascular permeability and subsequent reduction of post-ischemic or post-traumatic brain edema.
n3:synonym
LF16-0687MS
n3:proteinBinding
>97.7%
n3:IUPAC-Name
n4:271B62DE-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B62E4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B62E3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B62E0-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B62E1-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B62E2-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B62DC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B62DA-363D-11E5-9242-09173F13E4C5 n4:271B62DD-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B62DB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B62EA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B62EB-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B62E5-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B62E6-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B62E8-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B62E7-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B62E9-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
209733-45-9
n3:Bioavailability
n4:271B62F0-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B62F2-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B62F3-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B62EF-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B62EE-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B62F1-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B62DF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B62EC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B62ED-363D-11E5-9242-09173F13E4C5